NCT02824965 - Pembrolizumab + CVA21 in Advanced NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 9, 2017

Primary Completion Date

July 1, 2021

Study Completion Date

October 31, 2021

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Pembrolizumab

Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.

BIOLOGICAL

CVA21

CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells

Trial Locations (1)

3078

Austin Health, Heidelberg